For all these reasons, we believe it is better to retain the name TFE3-rearranged PEComa, which accurately identifies its clinical, pathological, and molecular characteristics and is well-known by clinicians and pathologists worldwide. The gene discussed is TFE3; the disease is neoplasm with perivascular epithelioid cell differentiation.